Amunix Inc. on Wednesday announced an agreement with Biogen Idec to research and develop novel, fully-recombinant blood factors with improved therapeutic properties.
The partnership will combine Mountain View-based Amunix's protein half-life engineering expertise and Biogen Idec's research, manufacturing and clinical development of recombinant blood factors for hemophilia.
No comments:
Post a Comment